China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version) - Wikidata - awgldk - TriplyDB

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)

http://www.wikidata.org/entity/Q26800148

about

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.

P2860

Q33779741-25CFCA2F-0451-4065-A72D-AA2A37EA299D

P2860

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)

http://www.wikidata.org/entity/Q26800148

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@ast

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@en

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@nl

type

label

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@ast

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@en

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@nl

prefLabel

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@ast

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@en

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@nl

P1433

Q26800148-5DED2C85-C788-4671-A52B-3C2F90D55E44

P1476

Q26800148-CD653F7D-B75D-4F1E-A032-ED34E83E998E

P2093

Q26800148-1C093F10-7F7B-4B85-8A5A-0A7E97CE834F

Q26800148-1C98E2BB-47A5-4586-AD04-EE7F179B80AA

Q26800148-1E72F8C1-2186-447E-96AE-22F2F564E32B

Q26800148-20287C1A-0069-4C92-95D8-4964106EC384

Q26800148-242FF599-675F-404B-B4A2-D317B804A9A0

Q26800148-24A5F3A0-C910-4C58-B175-78347BF67A46

Q26800148-34BF7163-804F-4390-8EEB-ED51F0405E41

Q26800148-35A5362F-25E1-4A54-AC0E-A61A5FEFCF75

Q26800148-35E4BA1F-4A20-4228-9B35-052FDC2AD921

Q26800148-41F10C81-C617-4DA3-BD19-4A2EC8A9F28A

P2860

Q26800148-0E4415D2-1F34-43FF-8DDF-97FFB0337664

Q26800148-14E17274-2988-412C-A526-B9F75498F9F7

Q26800148-16F50FB1-2366-45B3-A7DC-3182041CEC53

Q26800148-1D07876F-A7B6-407D-9CFC-B64085B970DB

Q26800148-3D33D245-57FA-4457-BD8E-96E9E8CB3E56

Q26800148-4A16DAFD-165A-4CAC-9954-B1FA7E91E28D

Q26800148-4B105B8A-4C9E-4F58-9503-371093DAD75A

Q26800148-522777AD-E2A8-4A1A-BDB0-9EFA2A38EA70

Q26800148-56B3C4D5-5953-456B-83FD-5C3FEA14EDFA

Q26800148-64BC8B30-CD7F-4038-BD7B-8934FBA9B38E

P304

Q26800148-F5346184-DE2D-4DA5-B2EA-ADB2FAC2B34F

P31

Q26800148-C4D5C210-72ED-4B4F-8177-BC5107859EEB

P356

Q26800148-8D42CE03-658B-4322-8FB5-8A87404F8A09

P433

Q26800148-D79833FE-3EF8-4E67-AFCE-AD94D34B96DC

P478

Q26800148-CDE08C92-C003-46CA-A544-473A9C79277E

P50

Q26800148-686AD8A4-A605-4C1D-930B-014317E4BECF

P577

Q26800148-EDE3D7D5-CAF3-48C3-8C1F-FD2774C76A9D

P698

Q26800148-92C4B3BC-7AA1-4675-9528-7A767CADBE09

P932

Q26800148-085664F7-1529-4D23-B1BE-5EC3CEB4F388

P356

J.ISSN.1009-3419.2015.07.01

P1433

Zhongguo fei ai za zhi

P1476

China Experts Consensus on Ico ...... ancer Treatment (2015 version)

@en

P2093

Aiqin Gu

http://www.w3.org/2001/XMLSchema#string

Baohui Han

http://www.w3.org/2001/XMLSchema#string

Caicun Zhou

http://www.w3.org/2001/XMLSchema#string

Changli Wang

http://www.w3.org/2001/XMLSchema#string

Cheng Huang

http://www.w3.org/2001/XMLSchema#string

Chong Bai

http://www.w3.org/2001/XMLSchema#string

Chunxue Bai

http://www.w3.org/2001/XMLSchema#string

Cuimin Ding

http://www.w3.org/2001/XMLSchema#string

Fang Li

http://www.w3.org/2001/XMLSchema#string

Gongyan Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

P304

397-400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2015.07.01

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26182862

http://www.w3.org/2001/XMLSchema#string

P932

6000245

http://www.w3.org/2001/XMLSchema#string